Catalyst Dossier · compiled by CeliA 🧫

NOVARTIS AG (NVSEF)

Biotechnology · market cap $269.0B · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Novartis AG (NVSEF) is a large-cap diversified pharmaceutical company with approximately 75,267 employees and a market capitalization of roughly $269 billion. The company maintains a broad late-stage pipeline spanning immunology, respiratory, oncology, cardiovascular, and infectious disease, with multiple Phase 3 programs currently active. The lead asset flagged in this dossier is MF59-eH1N1_f, a Phase 3 influenza vaccine candidate, though the company's near-term catalyst calendar is dominated by assets such as Ianalumab (Phase 3, October 2026), CTL019 (Phase 3, March 2027), and Remibrutinib (Phase 3, June 2027).

The catalyst path

2026-09-15 (est.)Phase 2 · TOUR006 - 20 MGimp 7/10
2026-09-24 (est.)Phase 2 · YTB323imp 7/10
2026-10-29 (est.)Phase 3 · Ianalumabimp 9/10
2027-01-29 (est.)Phase 2 · Alpelisibimp 7/10
2027-02-26 (est.)Phase 2 · BYL719imp 7/10
2027-03-02 (est.)Phase 2 · Cryptosporidium parvum oocysts (ABO809)imp 7/10
2027-03-31 (est.)Phase 3 · CTL019imp 9/10
2027-04-12 (est.)Phase 3 · Ianalumabimp 9/10

Pipeline

Asset	Phase	Indication
Investigator choice of chemotherapy	Phase 2	Nasopharyngeal Carcinoma
Sandostatin LAR Depot	Phase 2	Primary Insulin Hypersecretion
LFG316	Phase 2	Neovascular Age-elated Macular Degeneration (Wet AMD)
MF59-eH1N1_f	Phase 3	Influenza
inhaled corticosteroid therapy	Phase 2	Bronchial Asthma
Glycopyrronium bromide	Phase 3	Chronic Obstructive Pulmonary Disease
Fingolimod	Phase 3	Multiple Sclerosis
dovitinib	Phase 3	Solid Tumors
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine	Phase 3	Swine-Origin Influenza A H1N1 Virus
Midostaurin	Phase 2	Acute Myeloid Leukemia
Influenza virus vaccine	Phase 3	Influenza
Iptacopan (LNP023)	Phase 2	Age-Related Macular Degeneration
Enalapril	Phase 3	Hypertension
secukinumab 150 mg	Phase 3	Moderate to Severe Chronic Plaque-type Psoriasis
Rivastigmine	Phase 3	Vascular Dementia
Indacaterol 300 μg	Phase 3	Chronic Obstructive Pulmonary Disease
Formoterol	Phase 3	Chronic Obstructive Pulmonary Disease
Nidufexor	Phase 2	Diabetic Nephropathy
Mycophenolate mofetil (MMF)	Phase 3	Kidney Transplantation
DNK333 5 mg	Phase 2	Pruritus in Patients With Atopic Dermatitis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NVSEF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.